D.A. Davidson & CO. Reduces Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

D.A. Davidson & CO. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,098 shares of the biopharmaceutical company’s stock after selling 192 shares during the period. D.A. Davidson & CO.’s holdings in Alnylam Pharmaceuticals were worth $593,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quent Capital LLC grew its stake in shares of Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $38,000. GAMMA Investing LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $52,000. Lindbrook Capital LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 37.2% during the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 100 shares during the period. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $71,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ALNY. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. BMO Capital Markets reiterated an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. HC Wainwright upped their price target on Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $216.19.

View Our Latest Stock Report on ALNY

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $150.06 on Wednesday. The firm has a market cap of $18.98 billion, a P/E ratio of -55.99 and a beta of 0.41. The firm’s fifty day moving average is $149.41 and its 200-day moving average is $163.83. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same quarter in the previous year, the company posted ($1.40) EPS. The firm’s revenue was up 54.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.77 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Further Reading

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.